Dozens of widely prescribed medications can raise blood sugar enough to trigger a diabetes diagnosis, and some do it through mechanisms that have nothing to do with weight gain or lifestyle. Glucocorticoids, certain antipsychotics, statins, immunosuppressants, and even newer cancer therapies all carry documented diabetes risk. The type of diabetes that develops, how fast it appears, and whether it reverses after stopping the drug vary dramatically depending on the medication involved and on the person taking it.
Glucocorticoids Are the Most Common Culprits
If you have ever taken prednisone, dexamethasone, or another corticosteroid for more than a few days, your doctor may have warned you about blood sugar spikes. Glucocorticoids are among the most frequently prescribed drugs worldwide, used for everything from asthma flares to autoimmune conditions, and they are also the single most recognized cause of drug-induced diabetes. They work against you on multiple fronts: they make your tissues less responsive to insulin, they prompt your liver to produce more glucose, and they interfere with how fat tissue normally helps regulate metabolism.1PubMed Central. Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism The higher the dose and the longer you take them, the greater the risk. Short bursts of steroids for a week or two rarely cause lasting problems, but months of therapy at moderate-to-high doses can push someone with borderline blood sugar into frank diabetes.
Children receiving glucocorticoids for conditions like acute lymphoblastic leukemia face similar risks, and those who are older, overweight, or have a family history of diabetes are more likely to develop high blood sugar during treatment.2PubMed Central. Medication-induced hyperglycemia: pediatric perspective This matters because glucocorticoids are often medically necessary, and simply stopping them is not always an option. In these situations, monitoring blood sugar closely and intervening early becomes the practical strategy.
Antipsychotic Medications and Metabolic Disruption
The relationship between atypical antipsychotic medications and diabetes became a major concern in the early 2000s and has been studied extensively since. Not all antipsychotics carry the same risk. Olanzapine and clozapine sit at the top. In a large epidemiologic study, patients taking olanzapine had roughly a 70% higher risk of developing diabetes compared to those on older-generation antipsychotics, while clozapine showed a trend toward even higher risk, though with wider statistical uncertainty.3PubMed. The incidence of diabetes in atypical antipsychotic users differs according to agent–results from a multisite epidemiologic study By contrast, quetiapine, risperidone, aripiprazole, and ziprasidone showed no meaningful increase in diabetes risk in that same study. A separate review of 17 pharmacoepidemiologic studies reached a similar conclusion: olanzapine, but not risperidone, was consistently linked to a higher risk of new-onset diabetes, and six out of nine head-to-head comparisons found olanzapine carried significantly more risk than risperidone.4Annals of Clinical Psychiatry. Do Certain Atypical Antipsychotics Increase the Risk of Diabetes? A Critical Review of 17 Pharmacoepidemiologic Studies
Weight gain is part of the story, since olanzapine and clozapine are notorious for causing substantial weight increases. But it is not the whole story. Human studies have shown that olanzapine and aripiprazole can worsen insulin resistance even when body weight and body mass do not change, suggesting that some antipsychotics directly interfere with how the body handles insulin.5PubMed Central. Association Between Antipsychotic Medication Use and Diabetes For people who need antipsychotic therapy, the practical takeaway is that the choice of drug matters. If you are already at risk for diabetes because of weight, family history, or other factors, discussing a lower-risk antipsychotic with your prescriber is a reasonable conversation to have.
Statins and Blood Sugar
Statins are the most widely prescribed cholesterol-lowering drugs in the world, taken by tens of millions of people. The fact that they modestly raise diabetes risk is well established but often surprises patients. In one analysis, people on statin treatment had a 46% increased risk of developing type 2 diabetes compared with those not taking statins, driven by roughly a 24% decrease in insulin sensitivity and a 12% decrease in insulin secretion.6PubMed Central. Statins and risk of type 2 diabetes: mechanism and clinical implications That sounds alarming out of context, but it needs to be weighed against the cardiovascular benefits, which are substantial in people with high cholesterol or existing heart disease. For most patients, the reduction in heart attacks and strokes far outweighs the modest bump in diabetes risk. Still, if you are already borderline diabetic and your doctor puts you on a statin, it is worth monitoring your blood sugar more closely.
Thiazide Diuretics and Beta-Blockers
Thiazide diuretics like hydrochlorothiazide, often prescribed for high blood pressure, have long been associated with mild increases in blood sugar. The traditional explanation blamed potassium loss: the theory was that low potassium impaired insulin secretion. But the evidence on that link is mixed. One study that directly measured potassium changes and insulin levels during hydrochlorothiazide therapy found no correlation between how much potassium dropped and what happened to insulin, suggesting the mechanism is either more subtle or involves changes inside cells that blood tests do not capture.7PubMed Central. Lack of Correlation Between Thiazide-Induced Hyperglycemia and Hypokalemia: Subgroup Analysis of Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study Whatever the mechanism, the blood sugar increase from thiazides is typically small and clinically relevant mainly in people who are already prediabetic.
Beta-blockers carry a similar reputation, though the picture is nuanced. Older, non-selective beta-blockers like propranolol have a stronger association with worsened blood sugar control. Newer, more selective agents appear to be gentler on metabolism. A study comparing nebivolol and atenolol in people who already had type 2 diabetes and high blood pressure found that neither drug further worsened insulin sensitivity or lipid profiles.8Journal of Human Hypertension. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes So the blanket claim that “beta-blockers cause diabetes” oversimplifies the situation considerably. The specific drug, the dose, and the patient all matter.
Immunosuppressants After Organ Transplant
New-onset diabetes after organ transplantation is common enough that it has its own clinical name, post-transplant diabetes mellitus. Tacrolimus, one of the most widely used immunosuppressants in transplant medicine, is the primary driver. The drug directly damages the insulin-producing beta cells in the pancreas. Research has shown that tacrolimus activates a signaling pathway that, under conditions of even mild metabolic stress, leads to loss of beta-cell maturity and abolished insulin secretion. In studies using human islets transplanted into mice on a high-fat diet, tacrolimus reduced expression of a key transcription factor needed for normal insulin release.9Diabetes. Tacrolimus-Induced BMP/SMAD Signaling Associates With Metabolic Stress–Activated FOXO1 to Trigger β-Cell Failure Separate work has confirmed that tacrolimus accelerates the deterioration of beta-cell identity and function in the presence of insulin resistance and metabolic stress.10PubMed Central. Beta-Cell Dysfunction Induced by Tacrolimus: A Way to Explain Type 2 Diabetes?
Sirolimus, another immunosuppressant used in transplant care, impairs beta-cell function through a related but distinct pathway. Research in human islet grafts found that both tacrolimus and sirolimus caused elevated proinsulin-to-insulin ratios, a marker of beta-cell stress, along with changes in genes related to calcium signaling and insulin processing.11The Journal of Clinical Investigation. Tacrolimus- and sirolimus-induced human β cell dysfunction is reversible and preventable For transplant patients, this risk is unavoidable to some degree because the alternative is organ rejection. But dose adjustments, switching from tacrolimus to cyclosporine, or adding diabetes medications early can sometimes prevent or reverse the problem.12PubMed. Immunosuppressive drug-induced diabetes
Cancer Immunotherapy and a Different Kind of Diabetes
Immune checkpoint inhibitors have transformed cancer treatment, but they come with a unique diabetes risk that looks very different from the drug-induced diabetes caused by steroids or antipsychotics. These drugs work by releasing the brakes on the immune system so it can attack tumors. Occasionally, the unleashed immune system also attacks the insulin-producing cells in the pancreas, causing a form of autoimmune diabetes that closely resembles type 1 diabetes.13PubMed Central. Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes Patients typically present suddenly with very high blood sugar and often with diabetic ketoacidosis. About half have the same antibodies found in childhood-onset type 1 diabetes, and most lose the ability to make insulin rapidly, without the gradual “honeymoon phase” seen in typical type 1 diabetes.
The overall incidence is low. Across nearly 14,000 patients in 158 clinical trials involving PD-1 or PD-L1 checkpoint inhibitors, about 0.5% developed this immunotherapy-induced diabetes. However, the rate was higher with combination immunotherapy (roughly 0.9%) and lower when chemotherapy was given alongside the immunotherapy (about 0.3%).14JAMA Oncology. Immune Checkpoint Inhibitor–Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 Agents Despite those small percentages, the clinical impact is severe: 90% of affected patients required hospitalization at diagnosis, and 43% needed intensive care. Unlike steroid-induced diabetes, this form is typically irreversible. Once the immune system destroys the beta cells, lifelong insulin therapy is needed. This makes early recognition critical, and oncologists are increasingly monitoring blood sugar routinely during checkpoint inhibitor treatment.
A separate category of cancer drugs, those targeting the PI3K/Akt/mTOR signaling pathway, also cause hyperglycemia, though through a metabolic rather than autoimmune mechanism. Because this pathway is heavily involved in how insulin promotes glucose uptake, blocking it predictably leads to insulin resistance and high blood sugar.15PubMed. A targeted approach to phosphoinositide-3-kinase/Akt/mammalian target of rapamycin-induced hyperglycemia Patients on these drugs are routinely monitored, and the blood sugar elevations often improve once the drug is stopped or the dose is adjusted.
HIV Protease Inhibitors
People living with HIV who take protease inhibitor-based antiretroviral regimens face an increased risk of insulin resistance. Individual protease inhibitors vary in how strongly they push the body toward insulin resistance, which reflects differences in how each drug interacts with molecular targets involved in glucose transport, fat-cell signaling, and inflammatory pathways.16PubMed Central. HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models Newer antiretroviral regimens, particularly those based on integrase inhibitors rather than protease inhibitors, appear to carry less metabolic risk. For patients already on protease inhibitor-based therapy, switching regimens is one strategy, though it must be balanced against the effectiveness of HIV suppression.
Niacin
Niacin, or vitamin B3, is sometimes used at high doses to improve cholesterol profiles. It can raise blood sugar, but the effect is relatively modest. In the ADMIT study, niacin increased fasting glucose by about 8.7 mg/dL in participants who already had diabetes and by about 6.3 mg/dL in those without. In people with diabetes, niacin use led to a small but statistically significant increase in HbA1c of about 0.3%, while in people without diabetes, HbA1c did not change.17JAMA. Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease: The ADMIT Study For most people, this is clinically manageable. But if you already have diabetes and take high-dose niacin, those small glucose bumps can make control harder, so more frequent monitoring is sensible.
Who Is Most Vulnerable
Not everyone on these medications develops diabetes, and the variation from person to person is enormous. The strongest risk factors are the same ones that predispose you to type 2 diabetes in general: excess weight, a family history of diabetes, older age, and existing insulin resistance or prediabetes. For some medications, the hyperglycemia is dose-dependent and almost predictable, as with high-dose glucocorticoids. For others, it is sporadic and difficult to predict ahead of time.18BMJ. Medication-induced hyperglycemia: pediatric perspective Children with leukemia, for example, show higher rates of steroid-induced hyperglycemia when they are older, heavier, or have family members with diabetes. The same general pattern holds in adults.
Emerging research in pharmacogenomics suggests that genetic variation helps explain why one person develops diabetes on a given drug and another does not. Differences in genes that govern how a drug is metabolized or how insulin signaling pathways respond to interference can shift individual susceptibility.19PubMed. Drug-induced hyperglycaemia and diabetes: pharmacogenomics perspectives This is still a research frontier rather than a routine clinical tool, but it may eventually allow doctors to predict who is most at risk before prescribing a high-risk medication.
When Drug-Induced Diabetes Can Be Reversed
Whether drug-induced diabetes goes away depends almost entirely on what caused it and how much damage was done. The most reversible cases involve drugs that increase insulin resistance without directly destroying insulin-producing cells. Glucocorticoid-induced diabetes frequently improves or resolves once the steroid course ends, particularly if the patient did not have prediabetes beforehand. Statin-induced glucose changes are modest enough that stopping or switching statins (when appropriate) can normalize blood sugar in some patients, though statins are rarely stopped solely for this reason because of their cardiovascular benefits.
Post-transplant diabetes from tacrolimus is potentially reversible in some cases. Switching from tacrolimus to cyclosporine has been shown to improve or reverse glucose tolerance abnormalities in affected patients.12PubMed. Immunosuppressive drug-induced diabetes Research on human islet grafts has also suggested that the beta-cell dysfunction caused by tacrolimus and sirolimus can be reversed and even prevented under certain conditions.11The Journal of Clinical Investigation. Tacrolimus- and sirolimus-induced human β cell dysfunction is reversible and preventable On the other end of the spectrum, checkpoint inhibitor-induced diabetes is almost always permanent. The autoimmune destruction of beta cells leaves patients insulin-dependent for life, much like classic type 1 diabetes.20PubMed Central. Acute presentation of immunotherapy-related diabetes mellitus without ketoacidosis, low C-peptide or elevated HbA1c
Practical Steps If You Are on a High-Risk Medication
Awareness is the most powerful tool. If you are starting or currently taking any of the drug classes discussed above, knowing that blood sugar changes are possible puts you in a better position to catch them early. Clinicians should be monitoring patients on high-risk medications with periodic blood sugar checks, and patients themselves should know the classic symptoms of high blood sugar: excessive thirst, frequent urination, blurred vision, and unexplained fatigue.21PubMed. Drug-Induced Hyperglycaemia and Diabetes
For many of these medications, the diabetes risk does not mean the drug should be avoided. It means the risk should be managed. That might involve choosing a lower-risk alternative when one exists, adjusting doses, adding blood-sugar-lowering treatment if needed, or simply monitoring more frequently. Stopping a medically necessary drug because of theoretical diabetes risk, especially when the risk is small or manageable, is rarely the right call. The goal is informed prescribing: choosing the right drug for the right patient while keeping an eye on metabolic side effects. If you are concerned about a medication you are taking, bring it up with your prescriber rather than stopping on your own. The tradeoffs are worth discussing, and in many cases there are practical solutions that let you keep the benefits of the drug while minimizing the metabolic cost.